CCIA
TARS icon

Campbell & Co Investment Adviser’s Tarsus Pharmaceuticals TARS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,364
Closed -$2.08M – 1417
2025
Q4 		$2.08M Buy
25,364
+10,103
+66% +$754K 0.1% 317
2025
Q3 		$907K Buy
15,261
+4,988
+49% +$246K 0.07% 458
2025
Q2 		$416K Buy
+10,273
New +$462K 0.03% 853

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Campbell & Co Investment Adviser's TARS Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 25,364 shares — an estimated $2.08M sold.

Campbell & Co Investment Adviser first reported a position in TARS in Q2 2025 and held it in 3 quarters. The position peaked at $2.08M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 25,364 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $2.08M.
  • Campbell & Co Investment Adviser first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Tarsus Pharmaceuticals position peaked at $2.08M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.